III期-话题@MedSci

#III期#

681篇内容 | 2798人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, objectType=article, longId=182548, objectId=646d1825487e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646d1825487e, replyNumber=0, likeNumber=49, createdTime=2019-11-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646d1825487e, moduleTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646d1825487e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594666, encodeId=0c021594666d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019年美国肾脏病学会肾脏周：阿斯利康展示关键的roxadustat III期数据, objectType=article, longId=182204, objectId=1773182204d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1773182204d1, replyNumber=0, likeNumber=63, createdTime=2019-11-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1773182204d1, moduleTitle=2019年美国肾脏病学会肾脏周：阿斯利康展示关键的roxadustat III期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1773182204d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594665, encodeId=171615946657e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, objectType=article, longId=182123, objectId=bacc18212334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacc18212334, replyNumber=0, likeNumber=61, createdTime=2019-10-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacc18212334, moduleTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacc18212334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594664, encodeId=4416159466421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, objectType=article, longId=182069, objectId=fe64182069a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe64182069a8, replyNumber=0, likeNumber=0, createdTime=2019-10-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe64182069a8, moduleTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe64182069a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594663, encodeId=7f7f15946631b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=17, createdTime=2019-10-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594662, encodeId=900a159466259, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验, objectType=article, longId=181882, objectId=a91918188212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91918188212, replyNumber=0, likeNumber=55, createdTime=2019-10-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91918188212, moduleTitle=礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91918188212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594661, encodeId=4abc159466198, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, objectType=article, longId=181870, objectId=66f71818e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66f71818e0a7, replyNumber=0, likeNumber=13, createdTime=2019-10-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66f71818e0a7, moduleTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66f71818e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594660, encodeId=fcec1594660c1, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=16, createdTime=2019-10-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594659, encodeId=b9171594659dc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=10, createdTime=2019-10-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594658, encodeId=110315946584b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, objectType=article, longId=181811, objectId=3a1a18181105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a1a18181105, replyNumber=0, likeNumber=17, createdTime=2019-10-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a1a18181105, moduleTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a1a18181105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594657, encodeId=5d1c159465ece, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=62, createdTime=2019-10-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594656, encodeId=719c159465663, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, objectType=article, longId=181538, objectId=4e6d181538d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6d181538d7, replyNumber=0, likeNumber=76, createdTime=2019-10-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6d181538d7, moduleTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6d181538d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594655, encodeId=dffd159465529, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据, objectType=article, longId=181536, objectId=e56f1815365e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56f1815365e, replyNumber=0, likeNumber=59, createdTime=2019-10-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56f1815365e, moduleTitle=Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56f1815365e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594654, encodeId=b756159465403, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, objectType=article, longId=181451, objectId=7dae1814517d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dae1814517d, replyNumber=0, likeNumber=59, createdTime=2019-10-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dae1814517d, moduleTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dae1814517d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594653, encodeId=c0b91594653d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BMC Gastroenterology：微血管密度在 II期和III期结肠癌患者在的预后价值, objectType=article, longId=181123, objectId=0c5918112380, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5918112380, replyNumber=0, likeNumber=55, createdTime=2019-10-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5918112380, moduleTitle=BMC Gastroenterology：微血管密度在 II期和III期结肠癌患者在的预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c5918112380)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594652, encodeId=b209159465284, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet oncol：3期试验：度伐单抗治疗III期非小细胞肺癌, objectType=article, longId=180827, objectId=7c0318082ec2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c0318082ec2, replyNumber=0, likeNumber=52, createdTime=2019-10-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c0318082ec2, moduleTitle=Lancet oncol：3期试验：度伐单抗治疗III期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c0318082ec2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594651, encodeId=721b15946513b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, objectType=article, longId=180608, objectId=b0ed180608a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0ed180608a6, replyNumber=0, likeNumber=59, createdTime=2019-10-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0ed180608a6, moduleTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0ed180608a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594650, encodeId=ff3015946505e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, objectType=article, longId=180601, objectId=697618060195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697618060195, replyNumber=0, likeNumber=19, createdTime=2019-10-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697618060195, moduleTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697618060195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594649, encodeId=86791594649af, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Edasalonexent治疗杜兴氏肌营养不良症的III期PolarisDMD试验即将开始, objectType=article, longId=180378, objectId=cb441803e8da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb441803e8da, replyNumber=0, likeNumber=51, createdTime=2019-10-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb441803e8da, moduleTitle=Edasalonexent治疗杜兴氏肌营养不良症的III期PolarisDMD试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb441803e8da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594648, encodeId=26a315946488d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, objectType=article, longId=180370, objectId=a2be1803e048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2be1803e048, replyNumber=0, likeNumber=58, createdTime=2019-10-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2be1803e048, moduleTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2be1803e048)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据

2019-11-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019年美国肾脏病学会肾脏周：阿斯利康展示关键的roxadustat III期数据

2019-11-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究

2019-10-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究

2019-10-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2019-10-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验

2019-10-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点

2019-10-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2019-10-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据

2019-10-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果

2019-10-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据

2019-10-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点

2019-10-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BMC Gastroenterology：微血管密度在 II期和III期结肠癌患者在的预后价值

2019-10-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet oncol：3期试验：度伐单抗治疗III期非小细胞肺癌

2019-10-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果

2019-10-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功

2019-10-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Edasalonexent治疗杜兴氏肌营养不良症的III期PolarisDMD试验即将开始

2019-10-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究

2019-10-02

科室
- - 订阅+
  - 更多科室
工具
服务